Stock Events

Calliditas Therapeutics 

SEK117.2
5
+SEK0.2+0.17% Friday 15:29

Statistics

Day High
117.9
Day Low
115.1
52W High
141.9
52W Low
80.8
Volume
102,946
Avg. Volume
199,284
Mkt Cap
6.02B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

23MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-0.92
-0.52
-0.13
0.27
Expected EPS
-0.0779365092
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CALTX.ST. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetes, solid tumors, and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Ms. Renee Aguiar-Lucander
Employees
217
Country
SE
ISIN
SE0010441584
WKN
000A2JP36

Listings